Clarify Pharma PLC Correction to the Admission Document (6777G)
July 28 2021 - 2:00AM
UK Regulatory
TIDMPSYC
RNS Number : 6777G
Clarify Pharma PLC
28 July 2021
28 July 2021
Clarify Pharma PLC
("Clarify Pharma" or the "Company")
Correction to the Admission Document dated 11 June 2021
Clarify Pharma (AQSE: PSYC) has identified that the statement of
Directors' interests set out in the Company's Admission Document
dated 11 June 2021 ("Admission Document") was incorrect. The
disclosure on page 47 of the original admission document should
have stated that Patrick McBride owned 20,000,000 shares of the
Company via Ontario Inc. and Nicholas Lyth owned 500,000 shares of
the Company. There is no change to the stated amount of total
shares outstanding. The disclosure in the admission document should
be read with the above correction.
-END-
About Clarify Pharma
Clarify Pharma is an investment vehicle focusing on investing in
biotech and life sciences companies seeking to prove the safety and
efficacy of psychedelic-based substances. The Company looks to
identify investment opportunities in the life sciences sector
within the UK, Canada and other growing markets, with the objective
of generating long-term capital growth and building investments in
an R&D pipeline of companies which are discovering, developing,
or deploying safe and evidence-based psychedelic inspired medicines
and experiential therapies that alleviate mental health problems
and enhance wellbeing.
Clarify Pharma is working to assemble a portfolio of companies
that focus on the development of psychedelic inspired medicines and
experiential therapies for human clinical trials under the
supervision and strict adherence to the guidelines of the United
Kingdom's MHRA, Canada's Health Canada as well as similar
regulatory authorities in other jurisdictions where Clarify or its
Investee Companies operate.
The Company's Directors have an established track record,
experience and networks in the psychedelic, cannabinoid and media
industries, to drive value creation.
For further information please contact:
Clarify Pharma
Jon Bixby via Tancredi +44 207 887 7633
Executive Chairman
------------------------------
First Sentinel
------------------------------
Corporate Adviser
Brian Stockbridge +44 7876 888 011
------------------------------
Tennyson Securities
------------------------------
Corporate Broker
Peter Krens +44 207 186 9030
------------------------------
Tancredi Intelligent Communication
------------------------------
Media Relations
Catrina Daly
Emma Hodges +44 7727 153 868
Salamander Davoudi +44 7861 995 628
clarifypharma@tancredigroup.com +44 7957 549 906
------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXFFFSLDIIDFIL
(END) Dow Jones Newswires
July 28, 2021 02:00 ET (06:00 GMT)
Clarify Pharma (AQSE:PSYC)
Historical Stock Chart
From Apr 2024 to May 2024
Clarify Pharma (AQSE:PSYC)
Historical Stock Chart
From May 2023 to May 2024